Arzeda

United States - Seattle, WA - Washington

• 04/04/2022
• Series B
• $33,000,000

Arzeda, The Protein Design Company™, is a synthetic biology company that creates novel proteins, enzymes and specialty chemical products that compete on performance, cost and sustainability. Partnering with Fortune 500 companies, Arzeda has developed a portfolio of enzymes and specialty chemicals for polymers, pharmaceuticals, industrial chemicals and other advanced applications. More information at www.arzeda.com.

Related People

Alexandre ZanghelliniCo Founder

United Kingdom - Seattle, Washington,

Alexandre Zanghellini co-founded Arzeda and currently serves as its Chief Executive Officer. He leads Arzeda’s product and technology development and corporate strartegy. Alex is one of the key inventors of Arzeda’s synthetic biology platform for novel enzyme and metabolic pathway design and is a keen believer in the power of biotechnology to solve some of our biggest societal challenges. Before founding Arzeda, Alex held positions in research and development both in academia and industry. He holds a Ph.D. in biochemistry from the University of Washington in Seattle, a M.Sc. Eng. in computer engineering from ENSTA/ParisTech and a MS in computer science from the University of Paris Pierre et Marie Curie/Paris VI.

LinkedIn https://www.linkedin.com/in/alexandre-zanghellini/